BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27272809)

  • 1. SOX2 and ALDH1 as Predictors of Operable Breast Cancer.
    Shima H; Kutomi G; Satomi F; Maeda H; Hirohashi Y; Hasegawa T; Mori M; Torigoe T; Takemasa I
    Anticancer Res; 2016 Jun; 36(6):2945-53. PubMed ID: 27272809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of ALDH1, CD44, OCT4 and SOX2 in tongue squamous cell carcinoma and their association with disease progression and prognosis.
    Huang CF; Xu XR; Wu TF; Sun ZJ; Zhang WF
    J Oral Pathol Med; 2014 Aug; 43(7):492-8. PubMed ID: 24450601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract.
    Kitamura H; Torigoe T; Hirohashi Y; Asanuma H; Inoue R; Nishida S; Tanaka T; Fukuta F; Masumori N; Sato N; Tsukamoto T
    Mod Pathol; 2013 Jan; 26(1):117-24. PubMed ID: 22899292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of aldehyde dehydrogenase 1 and transcription factors in both primary breast cancer and axillary lymph node metastases as a prognostic factor.
    Ito M; Shien T; Omori M; Mizoo T; Iwamoto T; Nogami T; Motoki T; Taira N; Doihara H; Miyoshi S
    Breast Cancer; 2016 May; 23(3):437-44. PubMed ID: 25599843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1-3 lymph node metastases.
    Nogami T; Shien T; Tanaka T; Nishiyama K; Mizoo T; Iwamto T; Ikeda H; Taira N; Doihara H; Miyoshi S
    Breast Cancer; 2014 Jan; 21(1):58-65. PubMed ID: 22407396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
    Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
    Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of CD44 and SOX2 expression is correlated with a poor prognosis in esophageal adenocarcinoma patients.
    Honing J; Pavlov KV; Meijer C; Smit JK; Boersma-van Ek W; Karrenbeld A; Burgerhof JG; Kruyt FA; Plukker JT
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S657-64. PubMed ID: 24833101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer.
    Ohi Y; Umekita Y; Yoshioka T; Souda M; Rai Y; Sagara Y; Sagara Y; Sagara Y; Tanimoto A
    Histopathology; 2011 Oct; 59(4):776-80. PubMed ID: 22014057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.
    Fischer AK; Pham DL; Bösmüller H; Lengerke C; Wagner P; Bachmann C; Beschorner C; Perner S; Kommoss S; Fend F; Staebler A
    Virchows Arch; 2019 Oct; 475(4):479-488. PubMed ID: 31451895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of aldehyde dehydrogenase 1 in invasive primary breast tumors and axillary lymph node metastases is associated with poor clinical prognosis.
    Dong Y; Bi LR; Xu N; Yang HM; Zhang HT; Ding Y; Shi AP; Fan ZM
    Pathol Res Pract; 2013 Sep; 209(9):555-61. PubMed ID: 23916993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study.
    Yoshioka T; Umekita Y; Ohi Y; Souda M; Sagara Y; Sagara Y; Sagara Y; Rai Y; Tanimoto A
    Histopathology; 2011 Mar; 58(4):608-16. PubMed ID: 21371077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALDH1 Expression and Vasculogenic Mimicry Are Positively Associated with Poor Prognosis in Patients with Breast Cancer.
    Xing P; Dong H; Liu Q; Zhao T; Yao F; Xu Y; Chen B; Zheng X; Wu Y; Jin F; Li J
    Cell Physiol Biochem; 2018; 49(3):961-970. PubMed ID: 30184527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
    Morimoto K; Kim SJ; Tanei T; Shimazu K; Tanji Y; Taguchi T; Tamaki Y; Terada N; Noguchi S
    Cancer Sci; 2009 Jun; 100(6):1062-8. PubMed ID: 19385968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of ALDH1 and SOX2 diffuse staining pattern of oral squamous cell carcinomas correlates to lymph node metastasis.
    Michifuri Y; Hirohashi Y; Torigoe T; Miyazaki A; Kobayashi J; Sasaki T; Fujino J; Asanuma H; Tamura Y; Nakamori K; Hasegawa T; Hiratsuka H; Sato N
    Pathol Int; 2012 Oct; 62(10):684-9. PubMed ID: 23005595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased SOX2 expression in less differentiated breast carcinomas and their lymph node metastases.
    Huang YH; Luo MH; Ni YB; Tsang JY; Chan SK; Lui PC; Yu AM; Tan PH; Tse GM
    Histopathology; 2014 Mar; 64(4):494-503. PubMed ID: 24382260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer.
    Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
    Neoplasma; 2014; 61(3):352-62. PubMed ID: 24824938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype.
    Kida K; Ishikawa T; Yamada A; Shimada K; Narui K; Sugae S; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Breast Cancer Res Treat; 2016 Apr; 156(2):261-9. PubMed ID: 26975188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women.
    Proctor E; Kidwell KM; Jiagge E; Bensenhaver J; Awuah B; Gyan K; Toy K; Oppong JK; Kyei I; Aitpillah F; Osei-Bonsu E; Adjei E; Ohene-Yeboah M; Brewer RN; Fondjo LA; Owusu-Afriyie O; Wicha M; Merajver S; Kleer C; Newman L
    Ann Surg Oncol; 2015 Nov; 22(12):3831-5. PubMed ID: 25743329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
    Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
    BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.